Drug Profile
Research programme: haemophilia A cell therapy - Sernova
Latest Information Update: 29 Nov 2023
Price :
$50
*
At a glance
- Originator Sernova Corp
- Class Antihaemorrhagics; Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Haemophilia A; Type 1 diabetes mellitus
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 27 Nov 2023 Research programme: haemophilia A cell therapy - Sernova receives Orphan Drug status for Haemophilia A in USA
- 27 Nov 2023 Research programme: haemophilia A cell therapy - Sernova receives Rare Pediatric Disease Designation for haemophilia A in USA
- 30 Jan 2023 Preclinical development is still ongoing for Haemophilia A in Canada and Germany (SC, Implant)